
CNTB Stock Forecast & Price Target
CNTB Analyst Ratings
Bulls say
Connect Biopharma Hldgs is a promising investment opportunity for investors seeking exposure to the respiratory disease market due to its innovative treatment, positive clinical results, and experienced leadership.
Bears say
Connect Biopharma Hldgs is currently trading at a discounted value due to challenges in securing an established registrational pathway for its next-generation antibody rademikibart targeted towards interleukin-4-receptor alpha in the treatment of acute exacerbations of asthma and COPD, despite management's plans to propose Day 7 FEV1 as the Phase 3 primary endpoint. Investment risk also lies in the potential for the FDA to request an earlier time point, FEV1 AUC, or additional clinical outcomes. Despite positive data in China for atopic dermatitis and differentiation from dupilumab, the company's equity setup remains complicated, and its stock reaction will have implications for dilution and funding for future stages of development.
This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.
CNTB Analyst Forecast & Price Prediction
Start investing in CNTB
Order type
Buy in
Order amount
Est. shares
0 shares